Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
Abstract Background For HER2-positive early-stage breast cancer patients who have received neoadjuvant chemotherapy with trastuzumab and pertuzumab (HP), it remains unclear whether to intensify treatment with T-DM1 or to continue with HP therapy in the presence of residual disease identified in post...
Saved in:
| Main Authors: | Junxiao Wang, Yushuai Yu, Qisheng Lin, Xin Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-025-03909-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?
by: Wiebren Tjalma, et al.
Published: (2025-06-01) -
Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01) -
Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01) -
The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
by: Joseph Edward Haigh, et al.
Published: (2024-09-01) -
Development of Focal Nodular Hyperplasia Post Dual Anti-HER2 Blockade with Pertuzumab and Trastuzumab in a Patient with Breast Cancer: A Case Report and Literature Review
by: Udip Maheshwari, et al.